<DOC>
	<DOCNO>NCT02372604</DOCNO>
	<brief_summary>Chronic Spontaneous Urticaria ( CSU ) , define persistence daily almost daily urticaria 6 week , affect 0.5 % 1 % general population . In half case , last 2 year . It dramatically alter quality life , particular sleep , generate numerous consultation hospitalization , average annual cost per patient close 2000 euro Europe . The treatment base validate 2nd generation anti-H1 antihistamine dosage one tablet per day whose effectiveness satisfactory , however half time . In case severe CSU refractory treatment anti-H1 licensed dosage , therapeutic alternative exist , still off-label : monketulast , anti-leukotriene , ciclosporine methotrexate , immunosuppressant . Various study show important benefit expensive anti-IgE biological : omaluzimab . Several open study also suggest superior efficacy good tolerability anti-H1 high dosage ( double , triple quadruple ) include levocetirizine . The off-label use high dosage anti-H1 grow rapidly France , tend replace use anti-H1 first generation substitution another 2nd generation anti-H1 recommend French Society Dermatology . This study , aegis Urticaria Group French Society Dermatology , intend compare efficacy levocetirizine 4 tablets/day versus 1 tablet/day treatment CSU resistant anti-H1 licensed dosage .</brief_summary>
	<brief_title>Efficacy Levocetirizine Fourfold Dosage Chronic Spontaneous Urticaria</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Subject must ≥18 year age screening . Chronic spontaneous urticaria already treat antiH1 least two month without sufficient efficacy . Urticaria Activity Score ( UAS7 ) &gt; 12 randomization visit ( visit 2 ) . For female : Of childbearing potential : female must use acceptable method contraception period 1 month inclusion 1 month last study visit ; Of nonchildbearing potential : e.g . postmenopausal ( absence menstrual bleeding 1 year ) , hysterectomy bilateral ovariectomy tubal ligation . Patient agrees take treatment provide study . Willingness ability comply protocol requirement . Written informed consent give prior studyrelated procedure . Subject affiliate National Social Security System . Pregnancy , breastfeed plan pregnancy study . Inducible urticaria ( except immediate dermographism associate CSU ) Differential diagnosis CSU ( urticarial vasculitis ) . Known hypersensitivity antihistamine . Known hypersensitivity one product component , hydroxyzine piperazine derivative . Sleepiness disorder Epworth sleepiness scale &gt; 15 . Treatment systemic corticosteroid within month screen visit . Treatment montelukast within week screen visit . Treatment H2antihistamine within week screen visit . Treatment immunosuppressive drug ( e.g . methotrexate , cyclosporine , azathioprine , mycophenolate mofetil … ) within month screen visit . Known congenital galactosemia , glucose galactose malabsorption , lactase deficiency , lactose fructose intolerance . Swallowing disorder . Liver dysfunction transaminase great twice normal value . Renal failure creatinine clearance &lt; 50mL/min ( calculate MDRD formula ) . Regular excessive alcohol consumption . Unstabilized chronic disease treatment . Subject protect law ( adult guardianship , hospitalize public private institution reason study , incarcerate ) . Subject additional condition , opinion investigator , may interfere study assessment put subject risk . Linguistic mentally incapacity sign consent form . Subject exclusion period previous study participate another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Chronic spontaneous urticaria</keyword>
	<keyword>Levocetirizine</keyword>
	<keyword>H1-antihistamine</keyword>
	<keyword>Fourfold dosage</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Tolerance</keyword>
	<keyword>UAS7 ( Urticaria activity score )</keyword>
	<keyword>resistant</keyword>
</DOC>